Was COVID-19 the long overdue wake-up call for pharma supply chains?

It should have been...

Sharing a previous article

Today, I’m sharing an article I was to do for journal GMP Review (GMP = Good Manufacturing Practice), just after the dreaded C19 hit. This is it:

Is COVID-19 the long overdue wake-up call for pharma supply chains?

It’s a two-part article, and this is part 1. The abstract is below:

“This paper describes how the exclusive focus on non-clinical and clinical data collection during the development of medicines and healthcare products results in supply chains that are riddled with risk and issues.

In the main, this is due to little awareness among actors in the development process of the seminal impact decisions taken here can have on the quality, cost and lead-time performance of the future commercial supply chain.

In the author’s experience, things will only begin to improve if product developers open their minds to a totally new model for product development – one that begins with its end-users – patients and healthcare professionals.

The paper concludes with a cal…